Pluri (PLUR) Accounts Receivable : $0.00 Mil (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is Pluri Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Pluri's accounts receivables for the quarter that ended in Dec. 2023 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Pluri's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 0.00.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Pluri's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-1.26.

Pluri Accounts Receivable Historical Data

The historical data trend for Pluri's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pluri Accounts Receivable Chart

Pluri Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Accounts Receivable

Get a 7-Day Free Trial

1.24

1.25

1.11

0.96

0.36

Pluri Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Accounts Receivable	Get a 7-Day Free Trial															-	-	0.36	-	-

Pluri Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Pluri Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Pluri's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0.105	*	91
=	0.00

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Pluri's accounts receivable are only considered to be worth 75% of book value:

Pluri's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(30.62	+	0.75 * 0	+	0.5 * 0	-	34.947
-	0	-	2.218)	/	5.21
=	-1.26

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Pluri Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Pluri's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Pluri (PLUR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pluri Inc (NAS:PLUR) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

Y55:Germany

Address

MATAM Advanced Technology Park, Building No.5, Haifa, ISR, 3508409

Website

https://www.pluri-biotech.com

Pluri Inc is a biotechnology company, that creates cell-based products for commercial use and is pioneering a biotech revolution that promotes wellbeing and sustainability. The company's technology platform developed a three-dimensional, or 3D, technology platform for cell expansion with an industrial scale in-house Good Manufacturing Practice, or GMP, cell manufacturing facility.

Executives

Lorne Kenneth Abony	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Zami Aberman	officer: Chief Executive Officer	63 RABUTZKY STREET, RAANANA L3 43220
Varda Shalev	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Pinhas Doron Birger	director	MATAM PARK, BUILDING #5, HAIFA L3 3508409
Clover Wolf Capital - Limited Partnership	10 percent owner	BOODENHIMER 24, TEL AVIV L3 6200838
Rami Avraham Levi	director	MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Maital Shemesh-rasmussen	director	MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 3508409
Doron Shorrer	director	33 KOREH PLADORR ST, JERUSALEM L3 93393
Isaac Braun	director	9 ZEHARIA STREET, BENE BARAK L3 51540
Yaky Yanay	officer: Chief Financial Officer	ARGAMAN 14, SHIMSHIT L3 17906
Moria Kwiat	director	HAKFAR 11, KIRYAT ONO L3 55525
Israel Ben-yoram	director	24 BARKAN STREET, RISHON LEZION L3 00000
Chen Franco-yehuda	officer: Chief Financial Officer	MATAM ADVANCED TECHNOLOGY PARK, BUILDING NO. 5, HAIFA L3 31905
Mark Germain	director	WELLSFORD REAL PROPERTIES INC, 535 MADISON AVENUE, NEW YORK NY 10022
Erez Egozi	officer: Chief Financial Officer	MATAM PARK, BUILDING 05, HAIFA L3 31905